Harvard Bioscience
HBIO
100 hedge funds and large institutions have $178M invested in Harvard Bioscience in 2023 Q2 according to their latest regulatory filings, with 41 funds opening new positions, 27 increasing their positions, 20 reducing their positions, and 6 closing their positions.
16,300% more call options, than puts
Call options by funds: $164K | Put options by funds: $1K
583% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 6
54% more funds holding
Funds holding: 65 → 100 (+35)
40% more capital invested
Capital invested by funds: $127M → $178M (+$51M)
35% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 20
0.54% more ownership
Funds ownership: 7.16% → 7.69% (+0.54%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$9.43M |
| 2 |
State Street
Boston,
Massachusetts
|
+$2.74M |
| 3 |
Morgan Stanley
New York
|
+$2.15M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.12M |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$1.48M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Archon Capital Management
Seattle,
Washington
|
-$5.94M |
| 2 |
HA
Heartland Advisors
Milwaukee,
Wisconsin
|
-$1.92M |
| 3 |
2C
272 Capital
Dallas,
Texas
|
-$1.9M |
| 4 |
MIM
Meros Investment Management
Dallas,
Texas
|
-$1.71M |
| 5 |
PCM
Portolan Capital Management
Boston,
Massachusetts
|
-$1.43M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
101
Jane Street
New York
| – | -$208K | -4,943 | Closed |
|
|
GCP
102
GSA Capital Partners
London,
United Kingdom
| – | -$117K | -2,785 | Closed |
|
|
CS
103
Credit Suisse
Zurich,
Switzerland
| – | -$97K | -2,310 | Closed |
|
|
EAM
104
Empirical Asset Management
Wellesley,
Massachusetts
| – | -$84K | -2,000 | Closed |
|
105
Squarepoint
New York
| – | -$54.6K | -1,299 | Closed |
|
106
Ohio Public Employees Retirement System (OPERS)
Columbus,
Ohio
| – | -$36K | -863 | Closed |
|
HBIO Hedge Fund Activity: Q2 2023 in Review
100 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Harvard Bioscience (HBIO) for Q2 2023, worth a combined $178M — up 40% from $127M a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new HBIO positions and 6 closed out — a net gain of 35 holders — while 27 added to existing stakes and 20 trimmed.
The largest buyer was BlackRock, adding an estimated $9.43M. The largest seller was Archon Capital Management, cutting an estimated $5.94M.
- 100 institutional investors held Harvard Bioscience (HBIO) as of Q2 2023, up from 65 in Q1 2023.
- Funds reported $178M of Harvard Bioscience stock for Q2 2023, up 40% quarter-over-quarter.
- 41 funds opened new Harvard Bioscience positions in Q2 2023 and 6 closed out, a net change of +35 holders.
- The largest Harvard Bioscience buyer in Q2 2023 was BlackRock, an estimated $9.43M added.
- The largest Harvard Bioscience seller in Q2 2023 was Archon Capital Management, an estimated $5.94M sold.
Based on aggregated 13F filings for Q2 2023.